Reducing risk in thiopurine therapy

References

• Alves S, Amorim A, Ferreira F, Prata MJ. (2001). Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin Pharmacol Ther 70:165–74.
   PubMed Web of Science ®Google Scholar
• Alves S, Rocha J, Amorim A, Prata MJ. (2004). Tracing the origin of the most common thiopurine methyltransferase (TPMT) variants: preliminary data from the patterns of haplotypic association with two CA repeats. Ann Hum Genet 68:313–23.
   PubMed Web of Science ®Google Scholar
• Ansari A, Arenas M, Greenfield SM, et al. (2008). Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 28:973–83.
   PubMed Web of Science ®Google Scholar
• Ansari A, Elliott T, Baburajan B, et al. (2008). Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 28:734–41.
   PubMed Web of Science ®Google Scholar
• Appell ML, Berg J, Duley J, et al. (2013). Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics 23:242–8.
   PubMed Web of Science ®Google Scholar
• Arenas M, Duley J, Sumi S, et al. (2007). The ITPA c.94C > A and g.IVS2 + 21A > C sequence variants contribute to missplicing of the ITPA gene. Biochim Biophys Acta 1772:96–102.
   PubMed Web of Science ®Google Scholar
• Askanase AD, Wallace DJ, Weisman MH, et al. (2009). Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol 36:89–95.
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Takwale A, Tan E, et al. (2002). Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 147:324–30.
   PubMed Web of Science ®Google Scholar
• Blaker PA, Arenas-Hernandez M, Smith MA, et al. (2013). Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol 86:539–47.
   PubMed Web of Science ®Google Scholar
• Boonsrirat U, Angsuthum S, Vannaprasaht S, et al. (2008). Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism. Lupus 17:132–4.
   PubMed Web of Science ®Google Scholar
• Brem R, Karran P. (2012). Oxidation-mediated DNA cross-linking contributes to the toxicity of 6-thioguanine in human cells. Cancer Res 72:4787–95.
   PubMed Web of Science ®Google Scholar
• Brouwer C, Marinaki AM, Lambooy LH, et al. (2001). Pitfalls in the determination of mutant alleles of the thiopurine methyltransferase gene. Leukemia 15:1792–3.
   PubMed Web of Science ®Google Scholar
• Budhiraja P, Popovtzer M. (2011). Azathioprine-related myelosuppression in a patient homozygous for TPMT*3A. Nat Rev Nephrol 7:478–84.
   PubMed Web of Science ®Google Scholar
• Burchenal JH, Murphy ML, Ellison RR, et al. (1953). Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 8:965–99.
   PubMed Web of Science ®Google Scholar
• Calne RY. (1960). The rejection of renal homografts. Inhibition in dogs by 6-mercaptopurine. Lancet 275:417–8.
   Google Scholar
• Cargnin S, Genazzani AA, Canonico PL, Terrazzino S. (2018). Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis. Pharmacol Res 135:102–11.
   PubMed Web of Science ®Google Scholar
• Carter M, Jemth AS, Hagenkort A, et al. (2015). Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2. Nat Commun 6:7871.
   PubMed Web of Science ®Google Scholar
• Chang JY, Park SJ, Jung ES, et al. (2019). Genotype-based treatment with thiopurine reduces incidence of myelosuppression in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. doi.10.1016/j.cgh.2019.08.034.
   Web of Science ®Google Scholar
• Chao K, Wang X, Cao Q, et al. (2017). Combined detection of NUDT15 variants could highly predict thiopurine-induced leukopenia in chinese patients with inflammatory bowel disease: a multicenter analysis. Inflamm Bowel Dis 23:1592–9.
   PubMed Web of Science ®Google Scholar
• Cheung ST, Allan RN. (2003). Mistaken identity: misclassification of TPMT phenotype following blood transfusion. Eur J Gastroenterol Hepatol 15:1245–7.
   PubMed Web of Science ®Google Scholar
• Choi R, Sohn I, Kim MJ, et al. (2019). Pathway genes and metabolites in thiopurine therapy in korean children with acute lymphoblastic leukemia. Br J Clin Pharmacol 85:1585.
   PubMed Web of Science ®Google Scholar
• Coenen MJH, de Jong DJ, van Marrewijk CJ, et al.; TOPIC Recruitment Team. (2015). Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology 149:907–17.
   PubMed Web of Science ®Google Scholar
• Colleoni L, Kapetis D, Maggi L, et al. (2013). A new thiopurine s-methyltransferase haplotype associated with intolerance to azathioprine. J Clin Pharmacol 53:67–74.
   PubMed Web of Science ®Google Scholar
• Collie-Duguid ES, Pritchard SC, Powrie RH, et al. (1999). The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9:37–42.
   PubMedGoogle Scholar
• Colombel JF, Ferrari N, Debuysere H, et al. (2000). Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118:1025–30.
   PubMed Web of Science ®Google Scholar
• Coulthard SA, McGarrity S, Sahota K, et al. (2018). Three faces of mercaptopurine cytotoxicity in vitro: methylation, nucleotide homeostasis, and deoxythioguanosine in DNA. Drug Metab Dispos 46:1191–9.
   PubMed Web of Science ®Google Scholar
• Daehn I, Brem R, Barkauskaite E, Karran P. (2011). 6-Thioguanine damages mitochondrial DNA and causes mitochondrial dysfunction in human cells. FEBS Lett 585:3941–6.
   PubMed Web of Science ®Google Scholar
• Dorababu P, Naushad SM, Linga VG, et al. (2012). Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL. Pharmacogenomics 13:1001–8.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lamothe S, Yang HY, et al. (2000). Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705–13.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Yang H, Hassard PV, et al. (2002). 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122:904–15.
   PubMed Web of Science ®Google Scholar
• Elion GB. (1989). The purine path to chemotherapy. Science. 244:41–7.
   PubMed Web of Science ®Google Scholar
• Elion GB, Callahan S, Rundles RW, Hitchings GH. (1963). Relationship between metabolic fates and antitumor activities of thiopurines. Cancer Res 23:1207–17.
   PubMed Web of Science ®Google Scholar
• Evans WE, Hon YY, Bomgaars L, et al. (2001). Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 19:2293–301.
   PubMed Web of Science ®Google Scholar
• Fazel-Najafabadi E, Vahdat Ahar E, Fattahpour S, Sedghi M. (2015). Structural and functional impact of missense mutations in TPMT: an integrated computational approach. Comput Biol Chem 59:48–55.
   PubMed Web of Science ®Google Scholar
• Ford L, Prout C, Gaffney D, Berg J. (2004). Whose TPMT activity is it anyway? Ann Clin Biochem 41:498–500.
   PubMed Web of Science ®Google Scholar
• Gerbek T, Ebbesen M, Nersting J, et al. (2018). Role of TPMT and ITPA variants in mercaptopurine disposition. Cancer Chemother Pharmacol 81:579–86.
   PubMed Web of Science ®Google Scholar
• Higgs JE, Payne K, Roberts C, Newman WG. (2010). Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 11:177–88.
   PubMed Web of Science ®Google Scholar
• Hindorf U, Appell ML. (2012). Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function. J Crohn’s Colitis 6:655–9.
   Google Scholar
• Hung SI, Chung WH, Liou LB, et al. (2005). HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102:4134–9.
   PubMed Web of Science ®Google Scholar
• Khanna R, Bressler B, Levesque BG, et al.; REACT Study Investigators. (2015). Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet 386:1825–34.
   PubMed Web of Science ®Google Scholar
• Khera S, Trehan A, Bhatia P, et al. (2019). Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 83:341–8.
   PubMed Web of Science ®Google Scholar
• Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. (1995a). Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol 47:1141–7.
   PubMed Web of Science ®Google Scholar
• Krynetski EY, Schuetz JD, Galpin AJ, et al. (1995b). A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A 92:949–53.
   PubMed Web of Science ®Google Scholar
• Kurzawski M, Dziewanowski K, Ciechanowski K, Drozdzik M. (2005). Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A/*3C). Transplant Int 18:623–5.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim TJ, Kim ER, et al. (2017). Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn’s disease. PLoS One 12:e0188925.
   PubMed Web of Science ®Google Scholar
• Leipold G, Schütz E, Haas JP, Oellerich M. (1997). Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum 40:1896–8.
   PubMed Web of Science ®Google Scholar
• Lennard L, Cartwright CS, Wade R, et al. (2013). Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol 76:125–36.
   PubMed Web of Science ®Google Scholar
• Lennard L, Gibson BE, Nicole T, Lilleyman JS. (1993). Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 69:577–9.
   PubMed Web of Science ®Google Scholar
• Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. (1990). Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225–9.
   PubMed Web of Science ®Google Scholar
• Leung M, Piatkov I, Rochester C, et al. (2009). Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression. Int Med J 39:121–6.
   Google Scholar
• Levin RH, Landy M, Frei E. (1964). The effect of 6-mercaptopurine on immune response in man. N Engl J Med 271:16–22.
   PubMed Web of Science ®Google Scholar
• Liu Y, Meng Y, Wang L, et al. (2018). Associations between the NUDT15 R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: a meta-analysis. OncoTarget Ther 11:8309–17.
   PubMed Web of Science ®Google Scholar
• Liu YP, Wu HY, Yang X, et al. (2015). Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. PLoS One 10:e0121745.
   PubMed Web of Science ®Google Scholar
• Liu YP, Xu HQ, Li M, et al. (2015). Association between thiopurine S-methyltransferase polymorphisms and azathioprine-induced adverse drug reactions in patients with autoimmune diseases: a meta-analysis. PLoS One 10:e0144234.
   PubMed Web of Science ®Google Scholar
• Loennechen T, Yates CR, Fessing MY, et al. (1998). Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin Pharmacol Ther 64:46–51.
   PubMed Web of Science ®Google Scholar
• Maeda T, Sumi S, Ueta A, et al. (2005). Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab 85:271–9.
   PubMed Web of Science ®Google Scholar
• Marinaki AM, Ansari A, Duley JA, et al. (2004). Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14:181–7.
   PubMedGoogle Scholar
• Marinaki AM, Arenas M, Khan ZH, et al. (2003). Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics 13:97–105.
   PubMedGoogle Scholar
• Mazel P, Henderson JF, Axelrod J. (1964). S-Demethylation by microsomal enzymes. J Pharmacol Exp Ther 143:1–6.
   PubMed Web of Science ®Google Scholar
• Meggitt SJ, Gray JC, Reynolds NJ. (2006). Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 367:839–46.
   PubMed Web of Science ®Google Scholar
• Milosevic G, Kotur N, Krstovski N, et al. (2018). Variants in TPMT, ITPA, ABCC4 and ABCB1 genes as predictors of 6-mercaptopurine induced toxicity in children with acute lymphoblastic leukemia. J Med Biochem 37:320–7.
   PubMed Web of Science ®Google Scholar
• Moradveisi B, Muwakkit S, Zamani F, et al. (2019). ITPA, TPMT, and NUDT15 genetic polymorphisms predict 6-mercaptopurine toxicity in middle eastern children with acute lymphoblastic leukemia. Frontiers Pharmacol 10:916.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Nishii R, Lin TN, et al. (2017a). The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genom 27:236–9.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Nishii R, Perez-Andreu V, et al. (2016). NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nature Genet 48:367–73.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Yang YL, Nishii R, et al. (2017b). Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood 130:1209–12.
   PubMed Web of Science ®Google Scholar
• Naushad SM, Dorababu P, Rupasree Y, et al. (2019). Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 83:875–80.
   PubMed Web of Science ®Google Scholar
• Nelson JA, Carpenter JW, Rose LM, Adamson DJ. (1975). Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res 35:2872–8.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. (2006). Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130:1047–53.
   PubMed Web of Science ®Google Scholar
• Otterness D, Szumlanski C, Lennard L, et al. (1997). Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 62:60–73.
   PubMed Web of Science ®Google Scholar
• Pazmiño PA, Sladek SL, Weinshilboum RM. (1980). Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther 28:356–67.
   PubMed Web of Science ®Google Scholar
• Planet G, Fox IH. (1976). Inhibition of phosphoribosylpyrophosphate synthesis by purine nucleosides in human erythrocytes. J Biol Chem 251:5839–44.
   PubMed Web of Science ®Google Scholar
• Poppe D, Tiede I, Fritz G, et al. (2006). Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 176:640–51.
   PubMed Web of Science ®Google Scholar
• Rappaport HP. (1993). Replication of the base pair 6-thioguanine/5-methyl-2-pyrimidine with the large Klenow fragment of Escherichia coli DNA polymerase I. Biochemistry 32:3047–57.
   PubMed Web of Science ®Google Scholar
• Relling MV, Schwab M, Whirl-Carrillo M, et al. (2019). Clinical Pharmacogenetics Implementation Consortium Guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther 105:1095–105.
   PubMed Web of Science ®Google Scholar
• Roberts RL, Gearry RB, Bland MV, et al. (2008). Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet Genom 18:434–8.
   PubMed Web of Science ®Google Scholar
• Salavaggione OE, Wang L, Wiepert M, et al. (2005). Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genom 15:801–15.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Sutherland L, Pearson D, et al. (2000). Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev (2):CD000545.
   Google Scholar
• Sarcione EJ, Stutzman L. (1960). A comparison of the metabolism of 6-mercaptopurine and its 6-methyl analog in the rat. Cancer Res 20:387–92.
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Fischer C, Brockmeier D, et al. (2004). Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14:407–17.
   PubMedGoogle Scholar
• Schaeffeler E, Jaeger SU, Klumpp V, et al. (2019). Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genet Med 21:2145.
   PubMed Web of Science ®Google Scholar
• Shah SAV, Paradkar M, Desai D, Ashavaid TF. (2017). Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients. J Gastroenterol Hepatol 32:620–4.
   PubMed Web of Science ®Google Scholar
• Shih DQ, Nguyen M, Zheng L, et al. (2012). Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 36:449–58.
   PubMed Web of Science ®Google Scholar
• Sluiter RL, van Marrewijk C, de Jong D, et al. (2019). Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease. J Crohns Colitis 13:838–45.
   PubMed Web of Science ®Google Scholar
• Smith M, Blaker P, Patel C, et al. (2013). The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 67:161–9.
   PubMed Web of Science ®Google Scholar
• Sparrow MP, Hande SA, Friedman S, et al. (2005). Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 22:441–6.
   PubMed Web of Science ®Google Scholar
• Spire-Vayron de la Moureyre C, Debuysère H, Fazio F, et al. (1999). Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 9:189–98.
   PubMedGoogle Scholar
• Stocco G, Cheok MH, Crews KR, et al. (2009). Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 85:164–72.
   PubMed Web of Science ®Google Scholar
• Sumi S, Marinaki AM, Arenas M, et al. (2002). Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 111:360–7.
   PubMed Web of Science ®Google Scholar
• Szumlanski C, Otterness D, Her C, et al. (1996). Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15:17–30.
   PubMed Web of Science ®Google Scholar
• Tai HL, Fessing MY, Bonten EJ, et al. (1999). Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 9:641–50.
   PubMedGoogle Scholar
• Tai HL, Krynetski EY, Yates CR, et al. (1996). Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58:694–702.
   PubMed Web of Science ®Google Scholar
• Takagi Y, Setoyama D, Ito R, et al. (2012). Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: comparison with MTH1 and MTH2. J Biol Chem 287:21541–9.
   PubMed Web of Science ®Google Scholar
• Takatsu N, Matsui T, Murakami Y, et al. (2009). Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 24:1258–64.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Srimarthpirom S, Reungjui S, et al. (2003). Azathioprine-induced fatal myelosuppression in a renal-transplant recipient who carried heterozygous TPMT*1/*3C. Transplantation 76:265–6.
   PubMed Web of Science ®Google Scholar
• Tay BS, Lilley RM, Murray AW, Atkinson MR. (1969). Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. Biochem Pharmacol 18:936–8.
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S, et al. (2003). CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111:1133–45.
   PubMed Web of Science ®Google Scholar
• Ugajin T, Miyatani H, Demitsu T, et al. (2009). Severe myelosuppression following alopecia shortly after the initiation of 6-mercaptopurine in a patient with Crohn’s disease. Int Med 48:693–5.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gordon DA, Smythe HA, et al. (1973). Azathioprine in rheumatoid arthritis. A double-blind, cross over study. Arthritis Rheum 16:411–8.
   PubMed Web of Science ®Google Scholar
• Valerie NCK, Hagenkort A, Page BDG, et al. (2016). NUDT15 hydrolyzes 6-thio-deoxyGTP to mediate the anticancer efficacy of 6-thioguanine. Cancer Res 76:5501–11.
   PubMed Web of Science ®Google Scholar
• Van Dieren JM, Hansen BE, Kuipers EJ, et al. (2007). Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 26:643–52.
   PubMed Web of Science ®Google Scholar
• van Egmond R, Chin P, Zhang M, et al. (2012). High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther 35:1181–9.
   PubMed Web of Science ®Google Scholar
• van Gennep S, Konté K, Meijer B, et al. (2019). Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. Aliment Pharmacol Ther 50:484–506.
   PubMed Web of Science ®Google Scholar
• Vasudevan A, Gibson PR, Van Langenberg DR. (2019). Systematic review: cost-effective strategies of optimizing anti-tumor necrosis and immunomodulators in inflammatory bowel disease. Inflammat Bowel Dis 25:1462.
   PubMed Web of Science ®Google Scholar
• Walker GJ, Harrison JW, Heap GA, et al.; IBD Pharmacogenetics Study Group. (2019). Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease. JAMA 321:773–85.
   PubMed Web of Science ®Google Scholar
• Warren DJ, Andersen A, Slørdal L. (1995). Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res 55:1670–4.
   PubMed Web of Science ®Google Scholar
• Wee JS, Marinaki A, Smith CH. (2011). Life threatening myelotoxicity secondary to azathioprine in a patient with atopic eczema and normal thiopurine methyltransferase activity. BMJ 342:d1417.
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Sladek SL. (1980). Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651–62.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Kamatani N, Nishida Y, et al. (1984). Relationship between phosphorylation and cytotoxicity of 2-chloroadenosine and 6-methylmercaptopurine riboside in human cells. Biochimica Et Biophysica Acta 798:291–4.
   PubMed Web of Science ®Google Scholar
• Yang SK, Hong M, Baek J, et al. (2014). A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 46:1017–20.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Landier W, Yang W, et al. (2015). Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 33:1235–42.
   PubMed Web of Science ®Google Scholar
• Yan L, Zhang S, Eiff B, et al. (2000). Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Therap 68:210–9.
   PubMed Web of Science ®Google Scholar
• Yi ES, Choi YB, Choi R, et al. (2018). NUDT15 variants cause hematopoietic toxicity with low 6-TGN levels in children with acute lymphoblastic leukemia. Cancer Res Treat 50:872–82.
   PubMed Web of Science ®Google Scholar
• You C, Dai X, Yuan B, Wang Y. (2012). Effects of 6-thioguanine and S6-methylthioguanine on transcription in vitro and in human cells. J Biol Chem 287:40915–23.
   PubMed Web of Science ®Google Scholar
• Yuan B, Zhang J, Wang H, et al. (2011). 6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1. Cancer Res 71:1904–11.
   PubMed Web of Science ®Google Scholar
• Zgheib NK, Akika R, Mahfouz R, et al. (2017). NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children’s Cancer Center of Lebanon. Pediatric Blood Cancer 64:146–50.
   PubMed Web of Science ®Google Scholar
• Zhou H, Li L, Yang P, et al. (2018). Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer 18:516.
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang XD, Chao K, et al. (2016). NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn’s disease. Aliment Pharmacol Ther 44:967–75.
   PubMed Web of Science ®Google Scholar
• Zur RM, Roy LM, Ito S, et al. (2016). Thiopurine S-methyltransferase testing for averting drug toxicity: a meta-analysis of diagnostic test accuracy. Pharmacogenom J 16:305–11.
   PubMed Web of Science ®Google Scholar